By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Drugs and Therapies are discussed in a new report. According to news reporting originating in Aurora, Colorado, by NewsRx journalists, research stated, "Nanoparticles in porous microparticles (NPinPMP), a novel delivery system for sustained delivery of protein drugs, was developed using supercritical infusion and pressure quench technology, which does not expose proteins to organic solvents or sonication. The delivery system design is based on the ability of supercritical carbon dioxide (SC CO2) to expand poly(lactic-co-glycolic) acid (PLGA) matrix but not polylactic acid (PLA) matrix."
The news reporters obtained a quote from the research from the University of Colorado, "The technology was applied to bevacizumab, a protein drug administered once a month intravitreally to treat wet age related macular degeneration. Bevacizumab coated PLA nanoparticles were encapsulated into porosifying PLGA microparticles by exposing the mixture to SC CO2. After SC CO2 exposure, the size of PLGA microparticles increased by 6.9-fold. Confocal and scanning electron microscopy studies demonstrated the expansion and porosification of PLGA microparticles and infusion of PLA nanoparticles inside PLGA microparticles. In vitro release of bevacizumab from NPinPMP was sustained for 4 months. Size exclusion chromatography, fluorescence spectroscopy, circular dichroism spectroscopy, SDS-PAGE, and ELISA studies indicated that the released bevacizumab maintained its monomeric form, conformation, and activity. Further, in vivo delivery of bevacizumab from NPinPMP was evaluated using noninvasive fluorophotometry after intravitreal administration of Alexa Fluor 488 conjugated bevacizumab in either solution or NPinPMP in a rat model. Unlike the vitreal signal from Alexa-bevacizumab solution, which reached baseline at 2 weeks, release of Alexa-bevacizumab from NPinPMP could be detected for 2 months."
According to the news reporters, the research concluded: "Thus, NPinPMP is a novel sustained release system for protein drugs to reduce frequency of protein injections in the therapy of back of the eye diseases."
For more information on this research see: Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab. Molecular Pharmaceutics, 2013;10(12):4676-86. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)
Our news correspondents report that additional information may be obtained by contacting S.K. Yandrapu, Nanomedicine and Drug Delivery Laboratory, Dept. of Pharmaceutical Sciences, Dept. of Ophthlamology and Dept. of Bioengineering University of Colorado Anschutz Medical Campus , Aurora, Colorado 80045, United States. Additional authors for this research include A.K. Upadhyay, J.M. Petrash and U.B Kompella (see also Drugs and Therapies).
Keywords for this news article include: Aurora, Colorado, United States, North and Central America, Antineoplastic Monoclonal Antibodies, Antineoplastics, Bevacizumab, Drugs, Drugs and Therapies, Emerging Technologies, Nanoparticle, Nanotechnology, Technology, Therapy, Tyrosine Kinase Inhibitors, VEGF VEGFR Inhibitors.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC